Table 1 Overview of patients enrolled to study and demographics at time of enrolment
|  | Total (n = 120) | Standard of Care (Dex) (n = 46) | Standard of Care plus Spironolactone (SpiroDex) (n = 74) |
|---|---|---|---|
Age (mean, [SD]) | 48.8 [14.3] | 49.1 [13.9] | 48.6 [14.6] |
Gender | Male: 61.7% (n = 74) | Male 67.4% (n = 31) | Male 58.1% (n = 43) |
Female: 38.3% (n = 46) | Female 32.6% (n = 15) | Female 41.9% (n = 31) | |
Past Medical History | |||
 Diabetes Mellitus | 34.2% (n = 41) | 37.0% (n = 17) | 32.4% (n = 24) |
 Hypertension | 28.3% (n = 34) | 21.7% (n = 10) | 32.4% (n = 24) |
 Coronary artery disease | 5.8% (n = 7) | 8.7% (n = 4) | 4.1% (n = 3) |
 COPD | 1.7% (n = 2) | (n = 0) | 2.7% (n = 2) |
 Asthma | 3.3% (n = 4) | (n = 0) | 5.4% (n = 4) |
 Chronic Kidney Disease | 0.8% (n = 1) | (n = 0) | 1.4% (n = 1) |
 CVA | 0.8% (n = 1) | (n = 0) | 1.4% (n = 1) |
 Cancer | 0.8% (n = 1) | 2.2% (n = 1) | (n = 0) |
Baseline Clinical Findings | |||
 NEWS2 score Day 1a (median) | 3 | 4 | 3 |
 WHO OS score Day 1a (median) | 4 | 4 | 4 |
 ISARIC-4C score Day 1a (mean [SD]) | 8.0 [3.1] | 8.391 [3.09] | 7.743 [3.11] |
 SpO2/FiO2 ratio Day 1a (mean [SD]) | 181.9 [61.1] | 163.0 [58.3] | 193.7 [60.3] |
 D-Dimer μg/mL day 1a (mean [SD]) | 1.35 [1.97] | 1.798 [2.41] | 1.062 [1.58] |